Cargando…

Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study

Diabetes mellitus (DM) is a chronic metabolic disease which is independently associated with unfavorable clinical outcomes in patients with atrial fibrillation (AF). Few real-world data are available about the clinical performance of non-vitamin K oral anticoagulants (NOACs) among patients with atri...

Descripción completa

Detalles Bibliográficos
Autores principales: Russo, Vincenzo, Attena, Emilio, Rago, Anna, Melillo, Enrico, Di Micco, Pierpaolo, Papa, Andrea Antonio, Napolitano, Giovanni, D’Onofrio, Antonio, Golino, Paolo, Nigro, Gerardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356851/
https://www.ncbi.nlm.nih.gov/pubmed/32471222
http://dx.doi.org/10.3390/jcm9061621
_version_ 1783558577023090688
author Russo, Vincenzo
Attena, Emilio
Rago, Anna
Melillo, Enrico
Di Micco, Pierpaolo
Papa, Andrea Antonio
Napolitano, Giovanni
D’Onofrio, Antonio
Golino, Paolo
Nigro, Gerardo
author_facet Russo, Vincenzo
Attena, Emilio
Rago, Anna
Melillo, Enrico
Di Micco, Pierpaolo
Papa, Andrea Antonio
Napolitano, Giovanni
D’Onofrio, Antonio
Golino, Paolo
Nigro, Gerardo
author_sort Russo, Vincenzo
collection PubMed
description Diabetes mellitus (DM) is a chronic metabolic disease which is independently associated with unfavorable clinical outcomes in patients with atrial fibrillation (AF). Few real-world data are available about the clinical performance of non-vitamin K oral anticoagulants (NOACs) among patients with atrial fibrillation and diabetes. The aim of our propensity score-matched cohort study was to compare the safety and effectiveness of Edoxaban versus well-controlled vitamin K antagonists (VKAs) therapy among this population. In this study, we considered patients with AF and diabetes on Edoxaban or VKAs therapy included in the multicenter Atrial Fibrillation Research Database (NCT03760874). The occurrence of major bleedings (MB) and thromboembolic events (a composite of ischemic stroke, transient ischemic attack, systemic embolism) was respectively considered primary safety and effectiveness outcome. We identified 557 AF patients with diabetes who received Edoxaban (n: 230) or VKAs (n: 327) treatment. After propensity score matching analysis, 135 Edoxaban and 135 VKA recipients with similar clinical characteristics were evaluated. The mean follow-up was 27 ± 3 months. The incidence rate of thromboembolic events (TE) was 3.0 per 100 person-years (1.11 in Edoxaban vs. 1.9 in the VKA group, hazard ratio (HR): 0.59; 95% confidence interval (CI), 0.14 to 2.52; p = 0.48). The incidence rate of major bleedings (MB) was 3.7 per 100 person-years (1.2 in Edoxaban vs. 2.7 in the VKA group, HR: 0.43; 95% CI: 0.10 to 1.40; p = 0.14). The incidence rate of intracranial hemorrhage was 0.35 per 100 person-years in Edoxaban vs. 0.74 in the VKA group (HR: 0.49; 95% CI: 0.05 to 5.54; p = 0.56). A positive net clinical benefit (NCB) of Edoxaban over VKAs was found (+1.39). Insulin therapy (HR: 1.76, p = 0.004) and glycated hemoglobin (HR: 1.17, p = 0.002) were found to be independent predictors of TE; moreover, the concomitant use of antiplatelet drugs (HR: 2.41, p = 0.001) was an independent predictor of MB. Conclusions: Our data support the hypothesis of the safety and efficacy of Edoxaban for use in patients with AF and diabetes, justified by a favorable NCB over VKAs.
format Online
Article
Text
id pubmed-7356851
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73568512020-07-22 Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study Russo, Vincenzo Attena, Emilio Rago, Anna Melillo, Enrico Di Micco, Pierpaolo Papa, Andrea Antonio Napolitano, Giovanni D’Onofrio, Antonio Golino, Paolo Nigro, Gerardo J Clin Med Article Diabetes mellitus (DM) is a chronic metabolic disease which is independently associated with unfavorable clinical outcomes in patients with atrial fibrillation (AF). Few real-world data are available about the clinical performance of non-vitamin K oral anticoagulants (NOACs) among patients with atrial fibrillation and diabetes. The aim of our propensity score-matched cohort study was to compare the safety and effectiveness of Edoxaban versus well-controlled vitamin K antagonists (VKAs) therapy among this population. In this study, we considered patients with AF and diabetes on Edoxaban or VKAs therapy included in the multicenter Atrial Fibrillation Research Database (NCT03760874). The occurrence of major bleedings (MB) and thromboembolic events (a composite of ischemic stroke, transient ischemic attack, systemic embolism) was respectively considered primary safety and effectiveness outcome. We identified 557 AF patients with diabetes who received Edoxaban (n: 230) or VKAs (n: 327) treatment. After propensity score matching analysis, 135 Edoxaban and 135 VKA recipients with similar clinical characteristics were evaluated. The mean follow-up was 27 ± 3 months. The incidence rate of thromboembolic events (TE) was 3.0 per 100 person-years (1.11 in Edoxaban vs. 1.9 in the VKA group, hazard ratio (HR): 0.59; 95% confidence interval (CI), 0.14 to 2.52; p = 0.48). The incidence rate of major bleedings (MB) was 3.7 per 100 person-years (1.2 in Edoxaban vs. 2.7 in the VKA group, HR: 0.43; 95% CI: 0.10 to 1.40; p = 0.14). The incidence rate of intracranial hemorrhage was 0.35 per 100 person-years in Edoxaban vs. 0.74 in the VKA group (HR: 0.49; 95% CI: 0.05 to 5.54; p = 0.56). A positive net clinical benefit (NCB) of Edoxaban over VKAs was found (+1.39). Insulin therapy (HR: 1.76, p = 0.004) and glycated hemoglobin (HR: 1.17, p = 0.002) were found to be independent predictors of TE; moreover, the concomitant use of antiplatelet drugs (HR: 2.41, p = 0.001) was an independent predictor of MB. Conclusions: Our data support the hypothesis of the safety and efficacy of Edoxaban for use in patients with AF and diabetes, justified by a favorable NCB over VKAs. MDPI 2020-05-27 /pmc/articles/PMC7356851/ /pubmed/32471222 http://dx.doi.org/10.3390/jcm9061621 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Russo, Vincenzo
Attena, Emilio
Rago, Anna
Melillo, Enrico
Di Micco, Pierpaolo
Papa, Andrea Antonio
Napolitano, Giovanni
D’Onofrio, Antonio
Golino, Paolo
Nigro, Gerardo
Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study
title Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study
title_full Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study
title_fullStr Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study
title_full_unstemmed Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study
title_short Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study
title_sort clinical outcome of edoxaban vs. vitamin k antagonists in patients with atrial fibrillation and diabetes mellitus: results from a multicenter, propensity-matched, real-world cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356851/
https://www.ncbi.nlm.nih.gov/pubmed/32471222
http://dx.doi.org/10.3390/jcm9061621
work_keys_str_mv AT russovincenzo clinicaloutcomeofedoxabanvsvitaminkantagonistsinpatientswithatrialfibrillationanddiabetesmellitusresultsfromamulticenterpropensitymatchedrealworldcohortstudy
AT attenaemilio clinicaloutcomeofedoxabanvsvitaminkantagonistsinpatientswithatrialfibrillationanddiabetesmellitusresultsfromamulticenterpropensitymatchedrealworldcohortstudy
AT ragoanna clinicaloutcomeofedoxabanvsvitaminkantagonistsinpatientswithatrialfibrillationanddiabetesmellitusresultsfromamulticenterpropensitymatchedrealworldcohortstudy
AT melilloenrico clinicaloutcomeofedoxabanvsvitaminkantagonistsinpatientswithatrialfibrillationanddiabetesmellitusresultsfromamulticenterpropensitymatchedrealworldcohortstudy
AT dimiccopierpaolo clinicaloutcomeofedoxabanvsvitaminkantagonistsinpatientswithatrialfibrillationanddiabetesmellitusresultsfromamulticenterpropensitymatchedrealworldcohortstudy
AT papaandreaantonio clinicaloutcomeofedoxabanvsvitaminkantagonistsinpatientswithatrialfibrillationanddiabetesmellitusresultsfromamulticenterpropensitymatchedrealworldcohortstudy
AT napolitanogiovanni clinicaloutcomeofedoxabanvsvitaminkantagonistsinpatientswithatrialfibrillationanddiabetesmellitusresultsfromamulticenterpropensitymatchedrealworldcohortstudy
AT donofrioantonio clinicaloutcomeofedoxabanvsvitaminkantagonistsinpatientswithatrialfibrillationanddiabetesmellitusresultsfromamulticenterpropensitymatchedrealworldcohortstudy
AT golinopaolo clinicaloutcomeofedoxabanvsvitaminkantagonistsinpatientswithatrialfibrillationanddiabetesmellitusresultsfromamulticenterpropensitymatchedrealworldcohortstudy
AT nigrogerardo clinicaloutcomeofedoxabanvsvitaminkantagonistsinpatientswithatrialfibrillationanddiabetesmellitusresultsfromamulticenterpropensitymatchedrealworldcohortstudy